This Week: MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai’s PCN-101 Phase 2a Readout Tactogen Launches Community Stakeholder Initiative, Allowing Public to Purchase Equity Psychedelic Drug Developers Take Note: NICE’s Clarification of Spravato Coverage Rejection Might Prove Prophetic and lots more…


Previous articleWhy Did Psychedelics Relieve My Chronic Pain?
Next articleClearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market